We are excited to share the promising results from a valve-in-valve (ViV) study led by Dr. Anita Asgar and recently presented at New York Valves. The data demonstrated restoration of hemodynamic performance in five complex cases in which patients underwent a DurAVR® Transcatheter Heart Valve implantation after their surgical replacement valves failed.

Dr. Asgar emphasized, “This data set of valve-in-valve patients highlights the impact of the DurAVR® valve biomimetic design by restoring these patients’ hemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future.”